RGEN

RepligenC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$165.00

+12.1% vs current

Most likely

Base case

50%

Probability

Target price

$145.00

-1.5% vs current

B-

Bear case

25%

Probability

Target price

$108.00

-26.7% vs current

AI sentiment snapshot

Latest data as of 2026-06-23

AI commentary

Recent tone is modestly constructive because the only material packet news is the May 5 earnings release and follow-up coverage focused on a Q1 beat, organic-growth resilience, and higher EPS guidance. But buzz is low, social context is unavailable, immediate post-print market reaction is not established in the packet, and analyst-target breadth is unknown, so this remains a cautious monitoring-positive setup rather than a high-conviction rerating call.

RankAlpha Sentiment Codex - 2026-06-23

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-15catalystQ1 beat and EPS guidance raise improved the near-term setupHigh impact

On May 5, 2026, Repligen reported Q1 revenue of $194 million, up 15% reported and 11% organic, and raised FY26 adjusted EPS guidance to $1.97-$2.05 while reiterating 9%-13% organic growth, indicating better execution and order support than a simple revenue-range cut would suggest [#SEC-8K-2026-05-05].

2026-12-31catalystTransformation Office and Polymem divestiture could lift margin qualityHigh impact

Management said it launched a Transformation Office focused on site rationalization, product-line margin optimization, and IT/AI investment, while also divesting the non-core Polymem filtration business that generated $7 million of revenue and an operating loss in 2025; if execution holds, the mix shift can support better incremental margins through 2026 [#SEC-8K-2026-05-05].

2026-12-31catalystChina OEM partnership is a real but still early APAC growth leverMedium impact

Repligen disclosed an April 2026 partnership agreement in China structured as an OEM relationship to improve local manufacturing access and competitiveness, which could strengthen APAC share if commercialization progresses beyond initial setup [#SEC-8K-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-23 • Updated nightlySource: Internal modelMethodology